Clinical Trial: Clinical Trial of NXT007 for the Prophylactic Treatment of Hemophilia A in Infants and Children

U.S., Sept. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07838194) titled 'Clinical Trial of NXT007 for the Prophylactic Treatment of Hemophilia A in Infants and Children' on Sept. 17.

Brief Summary: The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of NXT007 prophylaxis in pediatric patients aged 0 to 11 years with severe or moderate congenital hemophilia A without factor VIII inhibitors or congenital hemophilia A of any severity (severe, moderate, and mild) with inhibitors (emicizumab-naive and treated). Patients with hemophilia A aged >=12 to <18 years old with a body weight of <40 kilograms (kg) are also able to participate.

Study Start Date: Nov. 30...